Pharmaco - Press Releases

Date	Title	Company
16-Feb-2022	Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus	AstraZeneca
16-Feb-2022	Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus	AstraZeneca
16-Feb-2022	European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults	Pfizer
16-Feb-2022	Boyds boosts specialist clinical expertise with new hire	Boyds
16-Feb-2022	Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform	Curve Therapeutics
16-Feb-2022	SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline	SpliceBio
16-Feb-2022	Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years	Moderna, Inc.
16-Feb-2022	Defence Therapeutics Inc.: DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER	Defence Therapeutics Inc.
16-Feb-2022	Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment	Relief Therapeutics Holding SA
15-Feb-2022	Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer	Intellia and ONK Therapeutics
15-Feb-2022	Immutep granted Australian patent for Eftilagimod Alpha, a soluble LAG-3 protein, in combination with a PD-1 pathway inhibitor	Immutep Limited
15-Feb-2022	Amolyt Pharma to Participate at Three Upcoming Investor Conferences	Amolyt Pharma
15-Feb-2022	Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults	Bavarian Nordic A/S
15-Feb-2022	Dante Labs Issued Genomic Medical Laboratory Authorization in Dubai	Dante Labs
15-Feb-2022	OncoZenge initiates toxicity study and announces modification to the clinical plan	OncoZenge
15-Feb-2022	Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million.	Newton Biocapital
15-Feb-2022	OKYO Pharma Limited ("OKYO" or the "Company") - OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease	OKYO Pharma Limited
15-Feb-2022	PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I	PureTech
15-Feb-2022	Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer	Janssen Pharmaceutical Companies of Johnson & Johnson
15-Feb-2022	Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer	Intellia Therapeutics, Inc.